2026 ICD-10-CM Diagnosis Code E88.11Partial lipodystrophy

ICD-10-CM Codes›E00–E89›E70-E88›E88

ICD-10-CM E88.11
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E88.11 is a billable ICD-10-CM diagnosis code for partial lipodystrophy. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026).

Code Identity

ICD-10-CM Code
E88.11
Billable Status
Yes — Valid for Submission
Code Describes
Partial lipodystrophy
Short Description
Partial lipodystrophy
Same as the full description in the CMS dataset.
Parent Code
E88.1
Lipodystrophy, not elsewhere classified

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE70-E88Metabolic disorders
CategoryE88Other and unspecified metabolic disorders
This CodeE88.11Partial lipodystrophy

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acquired partial lipodystrophy
  • AKT2-related familial partial lipodystrophy
  • Autosomal semi-dominant severe lipodystrophic laminopathy
  • CIDEC-related familial partial lipodystrophy
  • Familial partial lipodystrophy
  • Familial partial lipodystrophy Dunnigan type
  • Familial partial lipodystrophy Kobberling type
  • Insulin resistance
  • LIPE-related familial partial lipodystrophy
  • Lipodystrophy, partial, with Rieger anomaly, short stature, and insulinopenic diabetes mellitus
  • Malabsorption of glucose
  • Partial face-sparing lipodystrophy
  • Perilipin 1 related familial partial lipodystrophy
  • PPARG-related familial partial lipodystrophy

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Acquired partial lipodystrophy (APL)
  • Barraquer-Simons lipodystrophy
  • Familial partial lipodystrophy (FPLD)

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • APL(acquired partial lipodystrophy)
    • Barraquer(-Simons) disease or syndrome (progressive lipodystrophy)
    • Disease, diseased
      • Barraquer (-Simons') (progressive lipodystrophy)
    • Disease, diseased
      • Simons' (progressive lipodystrophy)
    • Lipodystrophia progressiva
    • Lipodystrophy
      • partial (acquired) (familial)
    • Lipodystrophy
      • progressive
    • Simons' disease or syndrome(progressive lipodystrophy)
    • Syndrome
      • Simons'

Clinical InformationClinical

  • Insulin Resistance

    diminished effectiveness of insulin in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

  • Metabolic Syndrome

    a cluster of symptoms that are risk factors for cardiovascular diseases and type 2 diabetes mellitus. the major components of metabolic syndrome include abdominal obesity; atherogenic dyslipidemia; hypertension; hyperglycemia; insulin resistance; a proinflammatory state; and a prothrombotic (thrombosis) state.

  • Acquired Partial Lipodystrophy

    partial lipodystrophy, the cause of which is not present at birth. examples include lipodystrophy associated with human immunodeficiency virus (hiv) therapy, and barraquer-simons syndrome, associated with c3 nephritic factor.

  • Familial Partial Lipodystrophy Type 2|FPLD2

    an autosomal dominant sub-type of familial partial lipodystrophy caused by mutation(s) in the lmna gene encoding prelamin-a/c.

  • Familial Partial Lipodystrophy|Congenital Partial Lipodystrophy

    an autosomal dominant inherited disorder that appears in childhood or adolescence. it is characterized by loss of adipose tissue in the extremities and accumulation of adipose tissue in the face and neck.

  • Partial Lipodystrophy

    loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.

  • Homeostatic Model Assessment of Insulin Resistance

    an assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.

  • Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome

    a condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. it is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.

  • Insulin Receptor Mutation - Associated Insulin Resistance Syndromes

    insulin resistance caused by inactivating mutation(s) in the insr gene encoding the insulin receptor.

  • Insulin Resistance

    decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.

  • Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance

    the determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.

  • Insulin Resistance Syndrome

    a cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. these abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.

  • Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome

    a syndrome of insulin resistance caused by mutation(s) in the insr gene, encoding the insulin receptor. this condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. this is the least severe of a spectrum of disorders; the other two conditions are rabson-mendenhall syndrome and donohoe syndrome.

  • Obesity-Associated Insulin Resistance

    insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.

Code History & ChangesHistory

New Code E88.11 was added to the ICD-10-CM code set for FY 2026, effective October 1, 2025.

Replacement E88.11 replaces the following previously assigned code(s):

  • E88.1 - Lipodystrophy, not elsewhere classified
FY 2026AddedAdded to the ICD-10-CM code setEffective October 1, 2025.
FY 2026CurrentRevised in the current code setEffective October 1, 2025 through September 30, 2026.

Questions About E88.11Overview

Is E88.11 (Lipodystrophy, not elsewhere classified) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report partial lipodystrophy on HIPAA-covered claims from October 1, 2025 through September 30, 2026.